Index

administrative process theory, health/trade conflict foundations and 85–7
advice see expert advice
aflatoxin 31, 33, 38, 93
Africa 31, 47
see also individually-named countries; developing countries
Agreements
Agriculture 1994 (GATT) 35, 217
Application of Sanitary and Phytosanitary Measures, on the see SPS Agreement 1994
Marrakesh 1994 51
Standards Code 25–6, 289, 301
Technical Barriers to Trade, on (TBT Agreement 1994) 207, 301
see also General Agreement on Tariffs and Trade; legislation
agricultural products
non-trade barriers rules’ development and 26
tariff substitution and 35
WTO case see Japan – Agricultural products
see also products
Alemanno, Alberto 174
Alma Alta Declaration (WHO 1978) 71
American Declaration on the Rights and Duties of Man 1948 71–2
anchoring
heuristics and bounded rationality, health/trade conflict foundations 89
animal health
defined 11
exposure assessment and 161
health/trade conflict and 18–20, 21, 22
protection, non-economic goals of health regulation and 74–7
public good, as 64–5
risk to health and 94, 98
science-based approach and 186
SPS Agreement disputes 32
WTO cases see Australia – Salmon; EC – Hormones
see also health
appropriate level of protection defined, SPS Agreement (Annex A(5)) 242–3
health (SPS Agreement Article 5.3) 105
right to set once risk presence established by scientific evidence and 29
setting, risk management and 247–8
arbitrary/unjustifiable discrimination (SPS Agreement Article 2.3) 254, 256–62
GATT lessons 248–56
negative trade effects minimization (SPS Agreement Article 5.4) 262–3
provisional measures and precautionary principle (SPS Agreement Article 5.7) 265–73
trade protection levels distinctions (SPS Agreement Article 5.5) 256–62
arbitrary/unjustifiable (SPS Agreement Article 5.6) 254, 263–5, 285–6
see also health protection; trade protection
Argentina 16, 32, 33, 219, 222, 244–5
Atik, Jeffery 147, 151, 183, 192
attributes
content, food safety as force for change in SPS Agreement disputes and 37–9
Index

health 10–12
instrumental values 74–5
international standards, guidelines or recommendations 122
intrinsic values 75
market failure 61
minimum threshold of rationality 193
necessary 250
non-tariff barriers 12
otherwise 182
paternalism 67
precautionary principle 169–70
procedural conformity 193
public health 10
regulation 58
regulatory harmonization 114
risk 92
risk assessment 157, 235–6, 241–2, 244, 271, 272, 273
risk assessment which is adequate 270
risk communication 155–6
risk management 155, 168–9
risks to human health 92–3
sanitary or phytosanitary measures 28
social regulation 60–61
socially optimal level of protection 104–5
sovereignty 111
trans-science 152
uncertainty 145–6
unjustifiable 254–5
welfare 95, 98

Department of Agriculture (USA) 45
Derry, Gregory N. 148, 151
developed countries
health regulation and 69
health/trade conflict resolution and 106–7
non-trade barriers rules’ development and 23–4
public participation in regulatory decision-making 40–43
risk perception in 127–9
scientific objectivity and 148
developing countries
health/trade conflict resolution and 106–7
North-South conflict and 46–7

special needs (SPS Agreement Article 10) 107
SPS measures’ trade impact 30–32, 33
standards, equivalence 125
subsidiarity and 298
dioxins, risk analysis and 164–5, 165–6
Directives
81/602 (European Commission) 209
90/220 (European Commission) 220
2001/18 (European Commission) 219, 220
2003/74/EC 213
see also legislation
discrimination
arbitrary/unjustifiable (SPS Agreement Article 2.3) 254, 256–62
disguised restriction on trade or (SPS Agreement Articles 2.3 and 5.5) 29, 103, 104, 157, 212, 215, 222
discriminatory measures justification (GATT Article XX) 7, 23, 117
see also necessity test
Disdier, Anne-Célia 30–31
divergence see regulatory divergence
dose-response assessment, risk assessment and 161
Douglas, M. 166
Dunkley, Graham 55, 56, 57, 100
duties see obligations

E.coli
food safety and 37
tariff substitution and 36
EC see European Commission
EC – Asbestos
analysis 226–7, 284, 287, 288
Canada and 202
facts 206–8
risk assessment and 228
risk management and 249–50, 251–2, 252–3, 279

EC – Biotech products
analysis 244, 285, 287, 290
facts 218–22
health/trade conflict resolution and 101
risk management and 270–73
**EC – Hormones**
- analysis 227, 285, 286, 287, 289, 290
- facts 208–13
- risk assessment and 231–3, 236–41, 246–7
- risk management and 247
- burden of proof 274
- expert advice 279–81
- review standard 276, 277
- SPS Agreement 257, 259, 260, 262, 265–7
- science-based approach and 184
- standard setting and 122

Echols, Marsha A. 184

economics
- behavioural law and, health/trade conflict foundations 87
- case for trade and, health/trade conflict foundations 52–3
- goals, normative theories of health regulation and 61–6
- goals other than, normative theories of health regulation and 66–77
- welfare, health regulation and 60

*The Economist* 38
effects
- negative trade, minimization of (SPS Agreement Article 5.4) 29, 103, 157, 262–3

efficiency
- Kaldor-Hicks, gains from trade and 53–4
- Pareto, gains from trade and 53, 54

Egypt 125
- see also Africa

England see United Kingdom

equivalence
- SPS Agreement (Article 4) 29, 125
- SPS Committee and 125
- standard setting 125

Environmental Protection Agency (EPA) (USA) 45, 164, 165, 166, 189–90

Euro-Retailer Working Group 15

European Commission (EC)
- animal health definition and 11
- *EC – Biotech products* and 220, 221, 222
- *EC – Hormones* and 209, 210, 211
- health definition and 10

science-based approach and 288
- see also European Union

European Communities (EC) see European Union

European Court of Justice 188

European Food Safety Authority 173, 174

European Parliament 210, 211

European Union (EU)
- *Brazil – Retreaded tyres* and 222, 223
- cases (WTO) see *EC – Asbestos; EC – Biotech products; EC – Hormones*

Directives see legislation
- Japanese import exclusions from compulsory approval and 15
- meat cases (WTO) see *EC – Hormones*
- non-trade barriers rules and 26, 27
- North-South conflict and 46, 47
- regulatory divergence and 43–4
- regulatory harmonization and 114, 118
- risk analysis and 152–3, 173–4
- risk perception and 132
- SPS measures’ trade impact and 31, 32, 33
- standards, equivalence 125
- subsidiarity principle and 112–13
- tariff substitution 36
- see also individually named Member States; European Commission

evidence see relevant evidence requirements; scientific evidence

exclusion
- imported products from compulsory approval, as non-tariff barrier to trade 14–15

expert
- risk perception by, public perception contrasted 129–30

expert advice
- science-based approach and 196–7
- SPS Agreement and 273, 278–84
- exposure assessment, risk assessment and 161–3

externalities
- negative, economic goals of health regulation and 61–3
Index

Farina, Cynthia R. 90
Feinberg, Joel 67–8
Feintuck, Mike 77–8
Ferrières, Madeleine 21
flora and fauna see animal health; plant health
Fontagné, Lionel 30–31
food safety
health cases analysis and 288–9
health/trade conflict and 19–21
non-tariff barriers to trade and 13, 14–15
regulatory divergence and 43–4
risk to health and 94, 98–9
science-based approach and 184
SPS Agreement disputes and 32, 36–40
SPS Committee and 38–9
standard setting and 124
WTO cases see Australia – Salmon;
EC – Biotech products; EC – Hormones; Japan – Agricultural products; Japan – Apples
see also human health
foot and mouth disease, import prohibitions and 13
France
Australian tariff substitution and 36
EC – Asbestos and 206–8, 228, 229, 249, 250, 251
EC – Hormones and 208
health/trade disputes in 1800s 16, 17–18, 19, 21–2
see also European Union
free trade objections, health/trade conflict foundations and 56–8
see also trade
G-90 see developing countries
Gains from trade, health/trade conflict foundations and 53–6
see also trade
The Gambia 32
see also Africa
Garcia, Frank J. 264
General Agreement on Tariffs and Trade 1947 (GATT)
Article I 23, 30
Articles III and III:4
like products 208, 226
national treatment obligation 23, 30, 117, 204, 223, 226
Article XI 30
Article XI.1 23, 204, 206
Article XX
discriminatory measures
justification 7, 23, 117
necessity test 229, 254, 255, 257, 263
Article XX(a) 188, 301
Article XX(b)
Brazil – Retreaded tyres and 223
EC – Asbestos and 208
interpretation by dispute panels and/or Appellate Body 284
regulatory harmonization and 117
risk assessment and 228–9
risk management and 248–9, 250, 254
science-based approach and 181, 188
SPS Agreement alongside 30
Thailand – Cigarettes and 204, 206, 225
Article XX(d) 250
Article XX(g) 101, 117
Australia – Salmon and 214
case for trade and 51
Japan – Agricultural products and 217
Japan – Apples and 218
non-trade barriers rules and 25, 26
primary focus 23, 293
risk assessment and 228–31
risk management and 248–56
SPS Agreement contrasted 7
science-based approach and 181, 188
standard setting and 122
see also Agreements; World Trade Organization
genetically modified (GM) foods
health cases analysis and 287–8
risk to health and 94, 98
risk perception and 132, 140
see also food safety; human health
Germany 17, 19, 20, 170
see also European Union
Gignilliat, John L. 20–21
Gostin, Lawrence O. 64, 68, 70
Green, Andrew J. 42
Hahn, Robert 139
harmonization
defined 121
SPS Committee role 122–3
see also regulatory harmonization
Hartley, Sarah 152, 153
Hassan, Ayesha 210–11
Hayden, S.S. 75
hazard identification
default assumptions and 165
risk assessment and 159–61
health
defined 10–12
international trade link 9
objectives see health/trade objectives
protection measures as non-tariff
trade barriers 12–15
right to 70–74
see also animal health; human health;
plant health; public health
health cases
analysis 225
key points 284–90
normative approach 225–7, 284
SPS Agreement interpretation see
SPS Agreement
Australia – Salmon 213–16
Brazil – Retreaded tyres 222–4
‘difficult’, identifying 95–9
EC – Asbestos 206–8
EC – Biotech products 218–22
EC – Hormones 208–13
identifying 92
Japan – Agricultural products 216–17
Japan – Apples 218
Thailand – Cigarettes 202, 204–6
health protection
necessity exception and (GATT
Article XX (b)) 30, 117, 181, 188, 284
Brazil – Retreaded tyres and 223
EC – Asbestos and 208
risk assessment and 228–9
risk management and 248–9, 250, 254
Thailand – Cigarettes and 204, 206, 225
socially optimal level of, defined 104–5
see also appropriate level of
protection; trade protection
health protection measures
non-tariff trade barriers, as 12–15
right to take necessary (SPS
Agreement Article 2.1) 181–2, 248
see also measures
health regulation
cases 203
health/trade conflict foundations and 58–60
alternative explanations 85–90
normative theories 60–61, 293–4
economic goals 61–6
non-economic goals 66–77
private interest theory, public
choice and 79–85
public interest theory 77–9
SPS Agreement and 59, 74, 76–7, 85
see also regulation; rules
health risk
health cases analysis and 290
health/trade conflict identification
and 92–4
health/trade conflict
1800s 16–23
aims of present study 5–6
foundations 51, 90–91, 293
health regulation see health
regulation
trade, case for 51–2
economic 52–3
free trade, objections to 56–8
gains from trade 53–6
identification
‘difficult’ cases 95–9
risk to health 92–4
SPS Agreement and 95, 99
non-trade barriers, rules development 23–8
resolution
GATT Article XX(b) 117, 181, 188, 208, 223, 248–9, 250, 254, 284
GATT Article XX(g) exception
and 101, 117
normative framework 102–7
Index

SPS Agreement and 100, 101, 102, 103, 106, 107
WTO and international law rules 100–102
SPS Agreement and 3, 4, 28–32, 91
SPS Agreement disputes 32–3, 34
health/trade objectives
conflict between 96–7
normative basis for balance of 294–7
Heijnsbergen, P. van 76
Heschl, Richard 19
heuristics
bounded rationality and 88–90
risk perception and 130–34
Hobbs, J.E. 260
hormones see EC – Hormones
Howse, Robert
health/trade conflict resolution and 102
science-based approach and 186–7, 198
SPS Agreement interpretation and 235, 251, 252
SPS Agreement science-based framework and 301
standard-setting and 115–16, 117–18
Hrudey, Steve E. 171, 172
Hudec, Robert 6–7
human health
dose-response assessment and 161
exposure assessment and 161
hazard identification and 160–61
protection obligation, non-economic goals of health regulation and 70–74, 103
risk perception and 134
risk to health and 93–4
risks to, defined 92–3
science-based approach and 186
uncertainty and 164
WTO cases see Brazil – Retreaded tyres; EC – Asbestos; EC – Biotech products; EC – Hormones; Thailand – Cigarettes
see also food safety; health; public health
human rights
health 70–74
participate in decision-making 74
see also rights
Iacavone, Leonardo 30
identification see hazard identification; health/trade conflict, identification
imports
exclusion from compulsory approval as non-tariff barrier to trade 14–15
prohibitions as non-tariff barrier to trade 13–14
see also products
India 33
Indonesia 33
information, standard setting and 116–17
see also cascades, informational; costs, information; deficits, information
interest see bounded self-interest; private interest theory; public interest theory
international law
rules, WTO and, health/trade conflict resolution 100–102
see also law
International Legal Commission (ILC) 101
International Office of Epizootics/International Animal Health Organization (OIE)
Australia – Salmon and 214, 242
harmonization under SPS Agreement and 122, 123, 124
regulatory harmonization and 121
relevant international standards, guidelines and recommendations, as 29, 182
subsidiarity and 297
international organizations, SPS
Committee contact with (SPS Agreement Article 12.3) 122–3
international standards
guidelines or recommendations, defined 122
higher trade protection level than implied in (SPS Agreement Article 3.3) 29, 122, 182
international trade, health link 9

Tracey Epps - 9781848443877
Downloaded from Elgar Online at 12/17/2018 12:44:08PM via free access
Italy 19, 208  
see also European Union

Japan 15, 27, 33  
Japan – Agricultural products  
analysis 233, 234, 235, 287  
facts 216–17  
risk management and 264, 268, 270, 274–5, 275–6, 279  
Japan – Apples  
analysis 233–4, 234–5, 285, 287  
facts 218  
risk assessment and 243–4  
risk management and 268–9, 270, 271, 275, 277

Jardine, Cindy G. 177  
Jasanoff, Sheila 45–6, 140, 145, 146, 147, 165

JECFA Reports 212, 237  
Johannes Althusius 112  
Jolls, Christine 87, 89  
Josling, Tim 36, 104–5, 210–11  
justice  
distributive, non-economic goals of health regulation and 66–7

Kagan, Robert A. 59  
Kahan, Dan M. 136, 137, 138, 140

Kenya 31–2  
see also Africa

Kerr, William A. 154, 260  
Kimbell, A.M. 31

Korea 14, 33  
Korea – Beef 250, 263, 288  
Kraemer, Helena Chmura 92–3  
Kraemer-Lowe, Karen see Lowe, Karen Kraemer-  
Kuhn, Thomas S. 149  
Kupfer, David J. 92–3

Lamming Report 212, 237  
Lamy, Pascal 199–200  
law  
behavioural, economics and, health/trade conflict foundations 87  
science and 143–6  
see also international law  
lawyers, scientific illiteracy of 146  
lead, risk to health and 94

Leebron, David W. 114, 116, 119, 124  
legislation  
Act to Prohibit the Manufacture and Sale of Certain Substitutes for Butter (Canada) 22  
Corn Laws (England) 17  
Decree No. 96-1133 (France) 206  
Executive Order 12866 of 1993 (USA) 189  
Federal Meat Inspection Act 1906 (USA) 84  
Foreign Animals Order 1878 (Great Britain) 18–19  
International Covenant on Civil and Political Rights 1948 (ICCPR) (UN) 74, 101  
International Covenant on Economic, Social and Cultural Rights 1966 (ICESCR) (UN) 71, 72, 101, 102  
Meat Inspection Act 1891 (Thailand) 204, 205  
Regulation 258/97 (European Commission) 219, 220  
Tobacco Act 1966 (Thailand) 204, 205  
Understanding on Rules and Procedures Governing the Settlement of Disputes (Dispute Settlement Understanding (DSU)) 213, 234, 276–7, 278–9  
see also Agreements; Charters; Conventions; Declarations; Directives; rules; Treaties

Leiss, William 171, 172  
level of protection see appropriate level of protection; health protection; trade protection

Lindseth, Peter L. 40–41  
Lowe, Karen Kraemer- 92–3  
Lowrance, William W. 128, 150–51  
mad cow disease (BSE)  
health cases analysis and 288  
import prohibitions and 13  
regulatory divergence and 45  
risk perception and 134, 135

Tracey Epps - 9781848443877
Downloaded from Elgar Online at 12/17/2018 12:44:08PM via free access
Index

Marette, Stephan 43
margarine, health/trade conflict and 21–2
margarine, health/trade conflict and 21–2
market failure
defined 61
economic goals of health protection and
information deficits and bounded rationality 65–6
negative externalities 61–3
public goods 63–5
non-economic goals of health regulation and
animal and plant health protection 74–7
community values 69–70
distributive justice 66–7
human health protection obligation 70–74
paternalism 67–9
McGarity, Thomas O. 193–5
measures
based on SPS Agreement (Article 3.1) 121–2, 182, 212
SPS Committee encouraging Members to take (Article 12.2) 122
conforming to SPS Agreement (Article 3.2) 122
sanitary or phytosanitary, defined 28
see also health protection, measures; provisional measures; SPS measures
mechanisms
psychological see heuristics
social, risk perception and 134–6
media, risk perception and 135–6
Mège-Mouriés, Hippolyte 21
MERCOSUR countries 223, 224, 256
Mexico 13, 33
Michaels, David 153–4
Mimouni, Mondher 30–31
Ministry of Agriculture, Fisheries and Food (UK) 45
Ministry of Agriculture, Forestry and Fisheries (Japan) 216
Monforton, Celeste 153–4
most favoured nation obligation (GATT Article I) 23, 30
Mozambique 31–2
see also Africa
mutual recognition see equivalence
National Research Council (NRC) (USA) 164, 168–9, 173, 174, 175, 177, 184
national treatment obligation (GATT Articles III and III:4) 23, 30, 117, 204, 223, 226
Neal, Mark 128–9
necessity exception
health protection and (GATT Article XX (b)) 30, 117, 181, 188, 284
Brazil – Retreaded tyres and 223
EC – Asbestos and 208
risk assessment and 228–9
risk management and 248–9, 250, 254
Thailand – Cigarettes and 204, 206, 225
public morals and (GATT Article XX (a)) 188
necessity test, (GATT Article XX) 229, 254, 255, 257, 263
see also discriminatory measures
justification
Neumann, Jan 263
New Zealand 36
non-tariff barriers
defined 12
health protection measures as 12–15
SPS Agreement and 293
see also General Agreement on Tariffs and Trade; tariff substitution; trade barriers
North America see United States of America
North-South conflict 46–7
objectivity
lack of, science-based approach and 183–4
notion of, science and risk analysis and 147–55
see also rationality threshold; scientific objectivity
objectives see health/trade objectives
obligations
human health protection 70–74, 103
most favoured nation (GATT Article I) 23, 30
national treatment (GATT Articles III and III:4) 23, 30, 117, 204, 223, 226
organizations see international organizations
Ogus, Anthony I. 65–6, 67, 68, 69, 70, 79
OIE see International Office of Epizootics/International Animal Health Organization
Orden, David 36, 104–5
Organization of American States (OAS) 72
Organization for Economic Cooperation and Development (OECD) 24, 31
Otsuki, Tsunehiro 31
outcome, risk to health and 93
ozone-depletion, science-based approach and 189
Panama 33
paternalism, non-economic goals of health regulation and 67–9
Paustenbach, Dennis J. 163
Pauwelyn, Joost 166–7, 196, 262
Peel, Jacqueline 186
Perdikis, N. 220
Perez, Oren 8, 186
Perren, John 19
Pfouts, R.W. 55–6
phylloxera vastatrix, health/trade conflict and 17–18
Pimenta Report 210
Pius XI, Pope 112
plant health
exposure assessment and 161
health/trade conflict and 17–18
non-tariff barriers to trade and 13, 15
protection, non-economic goals of health regulation and 74–7
public good, as 64, 65
regulation 12
risk to health and 94
science-based approach and 186
SPS Agreement disputes 32
uncertainty and 164
see also health
pleuro-pneumonia, health/trade conflict and 18–19
polychlorinated biphenys (PCBs), science-based approach and 194
population, risk to health and 93
positive requirements, as non-tariff barrier to trade 14
Posner, Richard A. 146, 154
Powell, Mark R. 164, 166, 167, 189–90
precaution, science and risk analysis and 169–73
precautionary principle defined 169–70
provisional measures and (SPS Agreement Article 5.7) 265–73
SPS Agreement interpretation by dispute panels and/or Appellate Body and 303–4
Prévost, Denise 277
private interest theory
public choice and, positive theories of health regulation and 79–85
probability
health cases analysis and 287–8
health/trade conflict resolution and 102, 104
risk to health and 93
probability neglect, risk perception and 131
products
biotech see EC – Biotech products like (GATT Articles III and III:4) 208, 226
see also agricultural products; imports
protection see appropriate level of protection; health protection; trade protection
protectionism
gains from trade and 56
health cases analysis and 290
health/trade conflict and 20–21, 22, 23
risk to health and 99
science-based approach and 186
provisional measures
SPS Agreement (Article 5.7) 217, 218, 222
precautionary principle and 265–73
right in absence of sufficient scientific evidence to take
183
see also measures
public participation in regulatory decision-making, as force for change for SPS Agreement disputes 40–43
risk analysis role 175–8
risk perception see risk perception, public and
public choice
private interest theory and, positive theories of health regulation and 79–85
public goods, economic goals of health regulation and 63–5
public health
defined 10
food safety and 37
health/trade conflict and 17, 18, 19, 20, 21–2
public good, as 64
see also health; human health
public interest theory, positive theories of health regulation and 77–9
public morals, necessity exception and (GATT Article XX (a)) 188, 301
public sentiment
health/trade conflict resolution and 102
science-based approach and 186, 190–91, 198–201

Rachlinski, Jeffrey J. 83, 90
rationality see bounded rationality; objectivity; scientific objectivity
rationality threshold, science-based approach and 193–6
refrigeration, health/trade conflict and 16–17
regulation
defined 58
economic, defined 60
mixed motives for 99, 102
response to public risk perception, as 139–41
social, defined 60–61
see also health regulation; rules
regulatory decision-making
domestic, reviewing, science-based approach and 191–201
public participation in, as force for change for SPS Agreement disputes 40–43
SPS Agreement and 42, 293
subsidiarity and 297–8
see also decision-making
regulatory divergence
SPS Agreement disputes, as force for change for 43–6
regulatory harmonization
defined 114
standard setting and arguments for and against 114–21
defined 113–14
SPS Agreement, under 121–4
see also harmonization
regulatory sovereignty
risk tolerance, in respect of 29
relevant evidence requirements (SPS Agreement Article 5.2), risk assessment and 246–7, 265, 266, 267, 283, 285
restrictions
qualitative, (GATT Article XI) 30
quantitative (GATT Article XI.I) 23, 204, 206
review standard, SPS Agreement and 273, 276–8
Reynolds, Christopher 70
Ricardo, David 52
rights
set appropriate level of protection once risk presence established by scientific evidence 29
take measures necessary to protect health (SPS Agreement Article 2.1) 181–2, 248
take provisional measures in absence of sufficient scientific evidence (SPS Agreement Article 5.7) 183
see also human rights
Rio Declaration (UN 1992) 101, 170
risk, defined 92
see also health risk
risk analysis
public role in 175–8
science and 143
   objectivity notion 147–55
   precaution 169–73
   values and 155–7
SPS Agreement and 143, 145, 147, 154, 157, 173, 175
see also risk management
risk assessment
defined 157, 235–6, 241–2, 244, 271, 272, 273
GATT lessons 228–31
health/trade conflict resolution and 103, 105–6
precaution in 172
qualitative 158, 159
quantitative 158–9
rationality of 166–7
requirements (SPS Agreement Article 5.1) 29, 235–45
Australia – Salmon and 215
discrimination/disguised restrictions and distinctions in level of protection and 261
EC – Biotech products and 222
EC – Hormones and 212
expert advice and 283
Japan – Apples and 218
provisional measures and precautionary principle and 265, 266, 267, 269, 272, 273
public risk perception and 288
science-based approach and 182
relevant evidence requirements 246–7, 265, 266, 267, 283, 285
risk management distinguished 173–5, 246
science and risk analysis and 157–68
scientific evidence requirements (SPS Agreement Article 2.2) 231–5, 267, 268, 270, 277, 288
which is adequate, defined 270
risk management
defined 155, 168–9
health/trade conflict resolution and 103–4
precaution in 172
risk assessment distinguished 173–5, 246
science and risk analysis and 168–9
setting appropriate level of protection see appropriate level of protection, setting
see also risk analysis
risk perception
health cases analysis and 288–9
health/trade conflict and 22
public and 127
cultural cognition or ‘normative bias’ 136–8
psychological mechanisms (heuristics) 130–34
regulating in response to 139–41
social mechanisms 134–6
WTO and 141–2
public/expert 105, 129–30, 288
Western society, in 127–9
risk tolerance, regulatory sovereignty in respect of 29
Roberts, Donna 36, 104–5, 210–11
Rodgers, Dr 281, 283
rules
international law, WTO and, health/trade conflict resolution 100–102
non-trade barriers, health/trade conflict and 23–8
see also health regulation; legislation; regulation
St Vincent and the Grenadines 15
salmonellosis, food safety and 37
Sandford, Ian 27–8
Schumacher, E.F. 57–8, 62, 100, 106
Science 189
science
domestic use of, mandating 188–90
junk, scientific objectivity and 153–4
lack of objectivity, science-based approach and 183–4
law and 143–6
risk analysis and see risk analysis, science and
trans-, scientific objectivity and 153
values and, relationship between 151
science-based approach, SPS Agreement and
criticisms of 184–5, 186–7

Tracey Epps - 9781848443877
Downloaded from Elgar Online at 12/17/2018 12:44:08PM via free access
mandating use of science
domestically 188
domestic regulatory decisions review
195, 196, 198, 199, 201
scientific evidence requirements
181–3
validating 190, 191
scientific evidence
Australia – Salmon and 283
‘available’ 29
criticism 4–5
EC – Hormones and 246–7, 265, 266, 285
insufficiency of 269
requirements (SPS Agreement Article
2.2)
consistency proviso 182, 218, 222
risk assessment and 231–5, 267, 268, 279, 270, 277, 288
risk analysis and 157
sufficient, right to take provisional measures in absence of (SPS
Agreement Article 5.7) 183
scientific objectivity
junk science and 153–4
science-based approach and 185–6
trans-science and 153
see also objectivity; rationality threshold
scientific uncertainty
health cases analysis and 289–90
health/trade conflict resolution and 102
risk to health and 99
science-based approach and 189–90, 198
see also uncertainty
Scott, C. 58
Scott, Dayna Nadine 184
Scott, Joanne 184–5
self-interest see bounded self-interest
Senegal 32
see also Africa
Sinclair, Upton 84
Sjoberg, Lennart 131
Skogstad, Grace 152, 153, 199
Slovic, Paul 130–31, 132, 135, 139–40, 141, 176
Smith, Kelly 166–7, 196
society
risk, risk perception and 128–9
Western see developed countries
Sokal, Alan D. 149–50
Soloway, Julie 9, 84, 191, 192, 277, 278
sovereignty see regulatory sovereignty
spongiform encephalopathy see mad cow
disease; transmissible spongiform
encephalopathy
SPS Agreement 1994
adoption of 3
Annex A 122
Annex A(2) 121
Annex A(4) 157, 235–6, 241–2, 244, 271, 272, 273
Annex A(5) 242–3
Article 2.1 181–2, 248
Article 2.2
consistency proviso 182, 218, 222
risk assessment and 231–5, 267, 268, 270, 277, 288
Articles 2.3 and 5.5
appropriate level of protection and 29
Australia – Salmon and 215
EC – Biotech products and 222
EC – Hormones and 212
GATT chapeau and 254
health case analysis generally and 256–62
health/trade objectives and 103, 104
risk analysis and 157
risk perception and 288
Article 3.1 121–2, 182, 212
Article 3.2 122
Article 3.3 29, 122, 182
Article 3.4 122
Article 4 29, 125
Article 5 246
Article 5.1
Australia – Salmon and 215, 261, 283
EC – Biotech products and 222, 272, 273
EC – Hormones and 212, 265, 266, 267
interpretation by WTO and 303
Japan – Apples and 218, 269
risk assessment requirements and 29, 235–45
risk perception and 288
science-based framework and 300
scientific evidence requirements
and 182
Article 5.2
Australia – Salmon and 283
criticism 4–5
EC – Hormones and 265, 266, 285
health case analysis generally and
246–7
interpretation by WTO and 302–3
risk analysis and 157
scientific evidence requirements
and
‘available’ 29
consistency proviso 182, 218, 222
risk assessment and 231–5, 267, 268, 279, 277, 288
Article 5.3 105, 288
Article 5.4 29, 103, 157, 262–3
Article 5.5 see Articles 2.3 and 5.5
above
Article 5.6
appropriate level of protection and
29–30
Australia – Salmon and 215
EC – Biotech products and 222
GATT chapeau and 254
health case analysis generally and
263–5
health/trade objectives and 103, 104
interpretation by dispute panels
and/or Appellate Body and
303
Japan – Agricultural products and
217
risk analysis and 157
risk management and 285–6
Article 5.7 183, 217, 218, 222, 265–73, 303–4
Article 7 217
Article 10 107
Article 11.1 273, 278–84
Article 12 32
Article 12.2 122
Article 12.3 122–3
Article 12.4 123
burden of proof 273–6
disputes under see SPS Agreement
disputes
draft of 26–8
EC – Asbestos and 227, 302
EC – Biotech products and 219
EC – Hormones and 209, 212, 227, 302–3
GATT contrasted 7
health/trade conflict and 3, 4, 28–32, 91
aims of present study 5–6
case for trade 52, 57
health regulation 59, 74, 76–7, 85
identification 92, 93–4, 95, 99
necessity determination
privileged health 4
resolution 100, 101, 102, 103, 106, 107
interpretation of
dispute panels and/or Appellate
Body by 302–4
flexibility 305
Japan – Agricultural products and
217
negotiation of 26
non-tariff barriers and 293
North-South conflict and 47
objectives of 3–4, 28
regulatory divergence in achieving
same 5
outline of present study and 7–8
‘post-discriminatory’ nature of 7
regulatory decision-making and 42, 293
review standard 273, 276–8
risk analysis and 143, 145, 147, 154, 157, 173, 175
risk perception 127, 130, 141
public/expert (Article 5.3) 105, 288
risk tolerance, regulatory sovereignty
in respect of 29
sanitary or phytosanitary measures,
defined 28
science-based approach and
criticisms of 184–5, 186–7, 298–301
mandating use of science
domestically 188
domestic regulatory decisions review 195, 196, 198, 199, 201
scientific evidence requirements 181–3
validating 190, 191
standard setting and 111, 113, 119, 120, 121–4, 126
subsidiarity and 297, 298
see also Agreements; World Trade Organization
SPS Agreement disputes forces for change for 35, 48
food safety 36–40
North-South conflict 46–7
regulatory decision-making, public participation in 40–43
regulatory divergence 43–6
tariff substitution 35–6
health/trade conflict and 32–3, 34
SPS Committee
equivalence and 125
harmonization role 122–3
encouraging Members to base measures on Agreement (Article 12) 122
establishment of 32
food safety and 38–9
SPS measures
publication requirement (SPS Agreement Article 7) 217
WTO Committee on (SPS Agreement Article 12) 32
see also measures
standard setting
mutual recognition 125
regulatory harmonization arguments for and against 114–21 defined 113–14
SPS Agreement, under 121–4
SPS Agreement and 111, 113, 119, 120, 121–4, 126
subsidiarity principle 112–13
standards see international standards; review standard; voluntary standards
Standards Code
adoption of 25
deficiencies in 25–6
objectives of 25
risk perception and 289
SPS Agreement science-based framework and 301
unnecessary obstacles to international trade (Art 2.1) 25
see also Agreements; legislation
Stigler, George J. 79
Stockholm Declaration (UN 1972) 76
subsidiarity harmonization and 297–8
standard setting and 112–13
substitution see tariff substitution
Sunstein, Cass R.
health/trade conflict foundations and 66, 69, 87, 88, 89
public interest theory and 79
public risk perceptions and WTO and 141
regulatory decision-making and 42
risk analysis and 170–71
risk perception and 127, 131, 132–4, 134–5, 137–8, 140–41
Swinbank, Alan 125
Switzerland 36, 125
Sykes, Alan O.
health/trade conflict foundations and 53–5, 56
science-based approach and 183
scientific evidence requirements and 5
SPS Agreement Article 5.6 and 264
standard setting and 114, 120–21, 122
Taneda, K. 31
Tanzania 31–2
see also Africa
tariff substitution disputes under SPS Agreement, as force for change for 35–6 see also non-tariff barriers
TBT Agreement 1994 see Standards Code
Teitel, Ruti G. 102
Thailand 32
Thailand – Cigarettes analysis 225–6, 287
facts 202, 204–6
risk assessment and 228
risk management and 248–9
Thaler, Richard 87, 89
Index

Treaties

Commercial, 1860 (Anglo-French) 17
Treaty of Amsterdam 1997 (European Union) 188
Treaty of Rome 1957 (EC Treaty) 112–13, 188–9
see also legislation

Trebilcock, Michael

health and international trade link and 9
health/trade conflict foundations and 68, 83, 90–91
review standard and 277, 278
science-based approach and 191, 192
standard setting and 115–16, 117–18
trichinella spiralis, health/trade conflict and 19–20, 21, 22

Tuerk, Elizabeth 251, 252, 263

Tyler, Tom 41

Uganda 31–2
see also Africa

uncertainty

risk analysis and 145–6, 163–4
trans-science, as 152
see also scientific uncertainty

Unilever Canada Inc. 22

United Kingdom (UK)

health/trade disputes in 1800s 16, 17, 18, 19, 20, 22
health regulation and 59
regulatory divergence and 45
risk analysis and 153
risk perception and 134, 135
see also European Union

United States of America (USA)

EC – Biotech products and 218, 220, 222
EC – Hormones and 209, 210, 211, 213
gasoline cases (WTO) see US – Reformulated Gasoline

health/trade disputes in 1800s 16, 17, 18, 19, 20, 21, 22
health regulation and 59, 62, 84
import prohibitions, health protection measures as non-tariff barriers to trade 13
Japan – Agricultural products and 216, 217
Index

Japan – Apples and 218
non-trade barriers rules and 26, 27
North-South conflict and 46, 47
regulatory decision-making 42
regulatory divergence and 43, 44, 45
regulatory harmonization and 115, 124
risk analysis and 153, 158, 162, 164–6, 170
risk assessment and 230, 231, 232, 233, 236–7, 244–5
risk management and 259, 264, 266, 274, 275–6
risk perception and 137, 139
science-based approach and 189, 193–5
SPS measures, trade impact 32, 33
Thailand – Cigarettes and 204, 205
see also Environmental Protection Agency; National Research Council
US – Reformulated Gasoline 250, 251, 254, 257
validation, science-based approach 190–91
values
  community, non-economic goals of health regulation and 69–70
  instrumental, defined 74–5
  intrinsic, defined 75
  role of see risk analysis, science and science and, relationship between 151
variant Creutzfeldt-Jakob (vCJD) disease, risk perception and 134
Venezuela 14–15, 33
Victor, Favid G. 262
Vogel, David 84
voluntary standards, as non-tariff barrier to trade 15

Wagner, Wendy 152
Walker, Vern 183, 240–41
Walzer, M. 70
Wiener, Jonathon B. 46
Wildavsky, A. 129, 166
Wilkinson, Susan B.T. 140
Williams, Pamela R.D. 163
willpower see bounded willpower
Wilson, J.S. 31

Wong, K.-Y. 31
Wooldridge, Dr 281–3
World Health Organization (WHO)
  Constitution 10, 11, 70–71
  EC – Hormones and 209, 212
  food safety and 40
  health/trade conflict identification and 98
  right to health as fundamental human right 71, 91
  risk assessment and 230
  science-based approach and 288
Thailand – Cigarettes and 205
World Trade Organization (WTO)
cases see Australia – Salmon; Brazil – Retreaded Tyres; EC – Asbestos; EC – Biotech products; EC – Hormones; Japan – Agricultural products; Japan – Apples; Korea – Beef; Thailand – Cigarettes; US – Reformulated Gasoline
health definition and 10
health/trade conflict and 51, 90
case for trade 58
health regulation 59
identification 92, 94, 95
resolution 100–102, 103, 107
non-tariff barriers and 12
North-South conflict and 47
regulatory decision-making and 42
review standard and 276, 277, 278
risk analysis and 143, 145, 154, 155, 166, 168, 175
risk perception and 127, 141–2
science-based approach and 181
assessing 183–91
domestic regulatory decisions, reviewing 191–201
standard setting and 111, 113, 122, 126
see also General Agreement on Tariffs and Trade; SPS Agreement

Yandle, B. see Baptist–Bootlegger theory
Zambia 47
see also Africa
Zarrilli, Simonetta 47
Ziman, John 147